A dystrophic Duchenne mouse model for testing human antisense oligonucleotides
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Exemplary here could be the hDMDdel52/mdx mouse, which carries the entire human DMD gene with a partial deletion of exon 52 that prevents expression of Dp427 and Dp140 (Veltrop et al., 2018; Yavas et al., 2020).”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Veltrop et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
X chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Research works printed but not linked: 40
- JR Mendell, 2013, Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy, Muscle Nerve, 48, 21, 10.1002/mus.23810 · DOI · Paper page
- SJ Moat, 2013, Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK), Eur J Hum Genet, 21, 1049, 10.1038/ejhg.2012.301 · DOI · Paper page
- EP Hoffman, 1987, Dystrophin: the protein product of the Duchenne muscular dystrophy locus, Cell, 51, 919, 10.1016/0092-8674(87)90579-4 · DOI · Paper page
- Y Kharraz, 2014, Understanding the Process of Fibrosis in Duchenne Muscular Dystrophy, Biomed Res Int, 2014, 965631, 10.1155/2014/965631 · DOI · Paper page
- FA Marden, 2005, Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging, Skeletal Radiol, 34, 140, 10.1007/s00256-004-0825-3 · DOI
- L Zhou, 2010, Targeting fibrosis in Duchenne muscular dystrophy, J Neuropathol Exp Neurol, 69, 771, 10.1097/NEN.0b013e3181e9a34b · DOI · Paper page
- AP Monaco, 1988, An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus, Genomics, 2, 90, 10.1016/0888-7543(88)90113-9 · DOI · Paper page
- EP Hoffman, 1988, Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy, N Engl J Med, 318, 1363, 10.1056/NEJM198805263182104 · DOI · Paper page
- JC van den Bergen, 2013, Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy, J Neurol Neurosurg Psychiatry
- S Cirak, 2011, Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study, Lancet, 378, 595, 10.1016/S0140-6736(11)60756-3 · DOI · Paper page
- NM Goemans, 2011, Systemic administration of PRO051 in Duchenne's muscular dystrophy, N Engl J Med, 364, 1513, 10.1056/NEJMoa1011367 · DOI · Paper page
- CL Bladen, 2015, The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations, Hum Mutat, 36, 395, 10.1002/humu.22758 · DOI · Paper page
- A Aartsma-Rus, 2009, Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations, Hum Mutat, 30, 293, 10.1002/humu.20918 · DOI · Paper page
- A Aartsma-Rus, 2017, FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides, Nucleic Acid Ther, 27, 67, 10.1089/nat.2017.0665 · DOI · Paper page
- YY Syed, 2016, Eteplirsen: First Global Approval, Drugs, 76, 1699, 10.1007/s40265-016-0657-1 · DOI · Paper page
- SD Wilton, 1999, Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides, Neuromuscul Disord, 9, 330, 10.1016/S0960-8966(99)00010-3 · DOI · Paper page
- MG Dunckley, 1998, Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides, Hum Mol Genet, 7, 1083, 10.1093/hmg/7.7.1083 · DOI · Paper page
- PA 't Hoen, 2008, Generation and characterization of transgenic mice with the full-length human DMD gene, J Biol Chem, 283, 5899, 10.1074/jbc.M709410200 · DOI
- M Veltrop, 2013, Generation of embryonic stem cells and mice for duchenne research, PLoS Curr, 5
- T Cermak, 2011, Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting, Nucleic Acids Res, 39, e82, 10.1093/nar/gkr218 · DOI · Paper page
- EL Doyle, 2012, TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction, Nucleic Acids Res, 40, W117, 10.1093/nar/gks608 · DOI · Paper page
- AH Beggs, 1991, Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies, Am J Hum Genet, 49, 54
- P Spitali, 2010, Accurate quantification of dystrophin mRNA and exon skipping levels in duchenne muscular dystrophy, Lab Invest, 90, 1396, 10.1038/labinvest.2010.98 · doi:10.1038/labinvest.2010.98
- A Aartsma-Rus, 2002, Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy, Neuromuscul Disord, 12, S71, 10.1016/S0960-8966(02)00086-X · DOI · Paper page
- JS Draper, 2007, Improved embryonic stem cell technologies, Handb Exp Pharmacol, 178, 107, 10.1007/978-3-540-35109-2_5 · DOI
- A Aartsma-Rus, 2014, Assessing functional performance in the mdx mouse model, J Vis Exp, 85
- AM Connolly, 2001, Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice, Neuromuscul Disord, 11, 703, 10.1016/S0960-8966(01)00232-2 · DOI
- M van Putten, 2012, Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains, Neuromuscul Disord, 22, 406, 10.1016/j.nmd.2011.10.011 · DOI
- M Hulsker, 2016, Accurate dystrophin quantification in mouse tissue; identification of new and evaluation of existing methods, Journal of Neuromuscular diseases, 1
- F Zhang, 2011, Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription, Nat Biotechnol, 29, 149, 10.1038/nbt.1775 · DOI · Paper page
- E Araki, 1997, Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy, Biochem Biophys Res Commun, 238, 492, 10.1006/bbrc.1997.7328 · DOI · Paper page
- Y Aoki, 2010, In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse, Mol Ther, 18, 1995, 10.1038/mt.2010.186 · DOI
- Y Echigoya, 2015, Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45–55 with a cocktail of vivo-morpholinos in mdx52 mice, Mol Ther Nucleic Acids, 4, e225, 10.1038/mtna.2014.76 · DOI
- Y Aoki, 2012, Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery, Proc Natl Acad Sci U S A, 109, 13763, 10.1073/pnas.1204638109 · DOI · Paper page
- HA Heemskerk, 2009, In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping, J Gene Med, 11, 257, 10.1002/jgm.1288 · DOI · Paper page
- B Wefers, 2016, Genome Editing in Mice Using TALE Nucleases, Methods Mol Biol, 1338, 229, 10.1007/978-1-4939-2932-0_17 · DOI
- M van Putten, 2012, The effects of low levels of dystrophin on mouse muscle function and pathology, PLoS One, 7, e31937, 10.1371/journal.pone.0031937 · DOI · Paper page
- M van Putten, 2013, Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice, FASEB J, 27, 2484, 10.1096/fj.12-224170 · DOI · Paper page
- JA Doudna, 2014, Genome editing. The new frontier of genome engineering with CRISPR-Cas9, Science, 346, 1258096, 10.1126/science.1258096 · DOI · Paper page
- CS Young, 2017, Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy, J Neuromuscul Dis, 4, 139, 10.3233/JND-170218 · DOI
Cited by
Kourounakis, A. P., Xanthopoulos, D., & Tzara, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21634 · Cited by 294
Understanding Duchenne muscular dystrophy-associated brain pathology
Verhaeg, M. A. T., Govaarts, R., & van Putten, M. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052302 · Cited by 5
Metadata
- Authors
- Veltrop, M., van Vliet, L., Hulsker, M., Claassens, J., Brouwers, C., Breukel, C., van der Kaa, J., Linssen, M. M., den Dunnen, J. T., Verbeek, S., Aartsma-Rus, A., & van Putten, M.
- ORCID
- van Putten, Maaike
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-02-21
- Volume
- 13
- Issue
- 2
- Pages
- e0193289
- ISSN
- 1932-6203
- Cited by
- 64
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A dystrophic Duchenne mouse model for testing human antisense oligonucleotides. https://app.cochat.ai/papers/10.1371/journal.pone.0193289
- The paper
- Veltrop, M., van Vliet, L., Hulsker, M., Claassens, J., Brouwers, C., Breukel, C., van der Kaa, J., Linssen, M. M., den Dunnen, J. T., Verbeek, S., Aartsma-Rus, A., & van Putten, M. (2018). A dystrophic Duchenne mouse model for testing human antisense oligonucleotides. PLOS ONE. https://doi.org/10.1371/journal.pone.0193289
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.